T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy

BACKGROUND: FOLFOX-based adjuvant chemotherapy is a benefit for high-risk stage II and stage III colon cancer after curative resection. But, the prognostic factor or predictive marker for the efficacy of FOLFOX remains unclear. This study was aimed to identify the prognostic value and cumulative imp...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Min Sung, Yoo, Jong Han, Kim, Kwang Hee, Bae, Ki Beom, Choi, Chang Soo, Hwang, Jin Won, Kim, Ji Hyun, Kim, Bo Mi, Kang, Mi Seon, Oh, Min Kyung, Hong, Kwan Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336700/
https://www.ncbi.nlm.nih.gov/pubmed/25889520
http://dx.doi.org/10.1186/s12957-015-0488-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336700/
https://www.ncbi.nlm.nih.gov/pubmed/25889520
http://dx.doi.org/10.1186/s12957-015-0488-7

Ejemplares similares